Narinder Pal Bhalla - 29 Jun 2026 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Reporting relationship: Chief Medical Officer
Issuer ticker: LXEO
Reported as of: 29 Jun 2026
Net transaction value: -$98,593
SEC form: 4
Accepted by SEC: 01 Jul 2026, 18:48:24 UTC
Prior SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Youjin Choi, Attorney-in-Fact

Key filing fact

Narinder Pal Bhalla filed Form 4 for Lexeo Therapeutics, Inc. (LXEO) on 01 Jul 2026.

Key facts

This page summarizes Narinder Pal Bhalla's Form 4 filing for Lexeo Therapeutics, Inc. (LXEO).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2026, 18:48.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: -$98,593.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002109299 Primary reporting owner

Bhalla Narinder Pal

Relationship: Chief Medical Officer
Address: C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK
Signature: /s/ Youjin Choi, Attorney-in-Fact
Signature date: 01 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LXEO transaction

Common Stock

Award

Transaction value
Shares: +55,000
Change %: +111%
Price: $0.000000^*
Shares after: 104,500
Date: 29 Jun 2026
Ownership: Direct

LXEO transaction

Common Stock

Sale

Transaction value: $98,593
Shares: -22,306
Change %: -21%
Price: $4.42
Shares after: 82,194
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs").

Footnote F2

This transaction was executed in multiple trades at prices ranging from $4.341 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

Includes 49,500 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.